SciBX
Science-Business eXchange

THE DISTILLERY

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Treating inflammation using mesenchymal stem cells (MSCs) overexpressing *P selectin glycoprotein ligand-1* (*PSGL-1*; *CD162*; *SELPLG*), *Sialyl-LewisX* (*SLeX*) and *IL-10*	MSCs overexpressing *PSGL-1*, *SLeX* and *IL-10* could be used to treat inflammation. In mice with lipopolysaccharide (LPS)-induced ear inflammation, retro-orbitally injected MSCs transfected with Psgl-1 and SLeX-synthesizing *α(1,3) fucosyltransferase* (*Fut7*) mRNA had stronger interactions with the inflamed endothelium than unmodified MSCs. In the same model, systemically injected MSCs transfected with *Psgl-1*, *Fut7* and *Il-10* mRNA increased Il-10 levels in the ear and decreased inflammation by about 50% compared with injected MSCs transfected with *Psgl-1* and *Fut7* mRNA. Next steps include testing the MSCs in several preclinical animal models. Wibi + Works LLC has Antimunocel, an anti-inflammatory, MSC-based product, in Phase I testing to treat rheumatoid arthritis (RA).	Cell engineering approaches patented; available for licensing	Levy, O. *et al. Blood*; published online Aug. 26, 2013; doi:10.1182/blood-2013-04-495119 **Contact:** Jeffrey M. Karp, Harvard Medical School, Boston, Mass. e-mail: jeffkarp.bwh@gmail.com

SciBX 6(39); doi:10.1038/scibx.2013.1114
Published online Oct. 10, 2013